Targeted radiation plus hormone therapy shows promise against resistant prostate cancer
NCT ID NCT04419402
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial investigates whether adding a targeted radiation therapy called Lu-PSMA to the standard hormone drug enzalutamide can delay cancer progression in men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. Participants receive either enzalutamide alone or enzalutamide plus four doses of Lu-PSMA over 24 weeks. The study measures how long it takes for PSA levels to rise, indicating cancer growth, and tracks imaging results and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lu-PSMA (177Lu-PSMA-617) and enzalutamide
What this could lead to
If successful, this combination could offer a new treatment option that delays cancer progression in men with advanced prostate cancer who have not yet had chemotherapy.
What could go wrong
This is a phase 2 trial with a relatively small number of participants, so results may not confirm benefit. Adding Lu-PSMA may increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
Calvary Mater Newcastle
Newcastle, New South Wales, 2298, Australia
-
Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
Fiona Stanley Hospital
Perth, Western Australia, 6150, Australia
-
Liverpool Hospital
Liverpool, New South Wales, 2170, Australia
-
Macquarie University Hospital
Macquarie Park, New South Wales, 2109, Australia
-
Monash Health
Clayton, Victoria, 3168, Australia
-
Northern Cancer Institute
Sydney, New South Wales, 2065, Australia
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3002, Australia
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Royal Brisbane and Women's Hospital
Brisbane, Queensland, 4029, Australia
-
Sir Charles Gairdner Hospital
Nedlands, Western Australia, 6009, Australia
-
St George Hospital
Kogarah, New South Wales, 2217, Australia
-
St Vincents Hospital
Darlinghurst, New South Wales, 2010, Australia
-
The Alfred Hospital
Melbourne, Victoria, 3004, Australia